1. Home
  2. BTE vs ACAD Comparison

BTE vs ACAD Comparison

Compare BTE & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Baytex Energy Corp

BTE

Baytex Energy Corp

HOLD

Current Price

$4.46

Market Cap

3.7B

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

SELL

Current Price

$21.37

Market Cap

4.4B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
BTE
ACAD
Founded
1993
1993
Country
Canada
United States
Employees
N/A
N/A
Industry
Meat/Poultry/Fish
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7B
4.4B
IPO Year
2004
2000

Fundamental Metrics

Financial Performance
Metric
BTE
ACAD
Price
$4.46
$21.37
Analyst Decision
Buy
Analyst Count
0
20
Target Price
N/A
★ $30.53
AVG Volume (30 Days)
★ 20.0M
1.5M
Earning Date
11-05-2026
11-04-2026
Dividend Yield
★ 1.36%
N/A
EPS Growth
N/A
★ 69.12
EPS
N/A
★ 0.20
Revenue
N/A
★ $726,437,000.00
Revenue This Year
$22.37
$18.71
Revenue Next Year
N/A
$12.44
P/E Ratio
★ $18.43
$102.93
Revenue Growth
N/A
★ 40.45
52 Week Low
$2.34
$18.39
52 Week High
$5.61
$30.96

Technical Indicators

Market Signals
Indicator
BTE
ACAD
Relative Strength Index (RSI) 37.98 45.59
Support Level $4.72 $19.70
Resistance Level $5.12 $22.92
Average True Range (ATR) 0.21 0.54
MACD -0.07 0.36
Stochastic Oscillator 7.78 79.44

Price Performance

Historical Comparison
BTE
ACAD

About BTE Baytex Energy Corp

Baytex Energy Corp is an oil and gas company. Geographically, the group operates in Canada and the United States. The company derives a majority of revenue from Canada. Its Canada segment includes the exploration, development, and production of crude oil and natural gas in Western Canada.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: